JW Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
JW Pharmaceutical has a total shareholder equity of ₩303.8B and total debt of ₩109.2B, which brings its debt-to-equity ratio to 35.9%. Its total assets and total liabilities are ₩636.9B and ₩333.1B respectively. JW Pharmaceutical's EBIT is ₩97.4B making its interest coverage ratio 18.5. It has cash and short-term investments of ₩95.9B.
Key information
35.9%
Debt to equity ratio
₩109.17b
Debt
| Interest coverage ratio | 18.5x |
| Cash | ₩95.91b |
| Equity | ₩303.77b |
| Total liabilities | ₩333.11b |
| Total assets | ₩636.88b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A001065's short term assets (₩361.0B) exceed its short term liabilities (₩254.8B).
Long Term Liabilities: A001065's short term assets (₩361.0B) exceed its long term liabilities (₩78.3B).
Debt to Equity History and Analysis
Debt Level: A001065's net debt to equity ratio (4.4%) is considered satisfactory.
Reducing Debt: A001065's debt to equity ratio has reduced from 77.3% to 35.9% over the past 5 years.
Debt Coverage: A001065's debt is well covered by operating cash flow (87.1%).
Interest Coverage: A001065's interest payments on its debt are well covered by EBIT (18.5x coverage).